What's Happening?
Acertis Pharmaceuticals has entered into an exclusive agreement with IBSA Institut Biochimique SA to license the U.S. commercial rights for Licart, a once-daily topical NSAID patch for acute pain management.
Licart, which utilizes advanced patch technology, offers rapid pain relief and sustained effects for up to 24 hours. This acquisition strengthens Acertis' portfolio in pain management, aligning with its strategy to provide innovative treatment options. The company plans to support Licart with patient assistance programs, including copay savings and educational resources for healthcare providers.
Why It's Important?
The licensing of Licart by Acertis Pharmaceuticals represents a significant advancement in pain management, particularly for patients with minor strains and sprains. The once-daily dosing and advanced delivery system of Licart offer a more convenient and effective alternative to traditional NSAIDs, potentially improving patient adherence and outcomes. This move also positions Acertis as a key player in the specialty pharmaceutical market, enhancing its competitive edge and expanding its market reach. The patient support initiatives further demonstrate Acertis' commitment to accessible healthcare solutions.
